- Home
- SON vs RARE Comparison
SON vs RARE Comparison
Compare SON & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SON
- RARE
- Stock Information
- Founded
- SON 1899
- RARE 2010
- Country
- SON United States
- RARE United States
- Employees
- SON N/A
- RARE N/A
- Industry
- SON Containers/Packaging
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- SON Consumer Discretionary
- RARE Health Care
- Exchange
- SON Nasdaq
- RARE Nasdaq
- Market Cap
- SON 4.6B
- RARE 4.2B
- IPO Year
- SON N/A
- RARE 2014
- Fundamental
- Price
- SON $46.84
- RARE $42.59
- Analyst Decision
- SON Buy
- RARE Strong Buy
- Analyst Count
- SON 6
- RARE 15
- Target Price
- SON $60.17
- RARE $93.13
- AVG Volume (30 Days)
- SON 819.2K
- RARE 656.5K
- Earning Date
- SON 02-18-2025
- RARE 02-13-2025
- Dividend Yield
- SON 4.44%
- RARE N/A
- EPS Growth
- SON N/A
- RARE N/A
- EPS
- SON 1.65
- RARE N/A
- Revenue
- SON $5,305,365,000.00
- RARE $560,230,000.00
- Revenue This Year
- SON N/A
- RARE $19.26
- Revenue Next Year
- SON $21.58
- RARE $36.92
- P/E Ratio
- SON $68.87
- RARE N/A
- Revenue Growth
- SON N/A
- RARE 29.01
- 52 Week Low
- SON $44.36
- RARE $37.02
- 52 Week High
- SON $61.73
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- SON 43.82
- RARE 44.76
- Support Level
- SON $44.36
- RARE $41.73
- Resistance Level
- SON $48.68
- RARE $44.98
- Average True Range (ATR)
- SON 1.13
- RARE 1.72
- MACD
- SON -0.06
- RARE -0.04
- Stochastic Oscillator
- SON 56.88
- RARE 18.03
About SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.